LIC of India trying to make a comeback after consolidation.Life Insurance Corporation of India is the largest multinational insurance corporation and an institutional investor with an asset under management of more than 45 trillion INR. The company offers insurance plans, pension plans, unit linked plans, withdrawn plans and health plans with many other group schemes.
Life Insurance Corporation CMP is 635.75. Negative aspects of the company are declining cash from operations and MFs are decreasing stake. Positive aspects of the company are improving annual net profits, no debt and zero promoter pledge.
Entry after closing above 643. Target of the call will be 653 and 666. Long term targets in the stock will be 681 and 704. Stop loss in the stock should be maintained at closing below 595.
Stockstobuy
Sandur Looks good for investment for Long term CMP 772Sandur Looks good for investment for Long term CMP 772,
Strong BS and Fundaments along with integrity and positive management approach.
Share price may test 1700 levels, after that may reach to 2300++ in longer run.
Keep eye on it and research from your side as well before investing.
VZTextbook Capitulation formation, very slow mover this is a weekly chart so analyze for your long term ports, dividend at this price is 8.3%, company is flush with cash so no signs of dividend being a problem. if you can lock in dividend at this price and catch any potential upside in price, this could be a jackpot trade.
Unveiling the Potential of Pfizer Pharmaceutical Stock in 2023Are you searching for a lucrative investment opportunity that promises great returns in 2023? Look no further as we unveil the hidden potential of Pfizer Pharmaceutical stock. In this blog post, we will delve into the compelling reasons why investing in Pfizer is not only a smart move but also an incredibly exciting. From groundbreaking innovations to robust financial performance, join us as we explore why Pfizer is poised to be a game-changer in the pharmaceutical industry and how you can reap substantial rewards by including it in your investment portfolio. Don’t miss out on this exclusive insight into what could be your most profitable venture yet!
Monthly price action is supporting a strong bullish correction in the following months. Pfizer is one of the world’s leading pharmaceutical companies and was at the forefront of developing a vaccine for Covid-19 in 2020. The stock price reflected the impact of the vaccine until December 2021, when the stock plunged, losing almost 50% of its value. It’s then when a longer-term demand imbalance takes control and helps us make a high-probability decision to buy and hold shares of Pfizer PFE stock.
Abbott Laboratories in a bull flag.Abbott Labratories - 30d expiry - We look to Buy a break of 109.51 (stop at 106.31)
The primary trend remains bullish.
This stock has seen good sales growth.
Expect trading to remain mixed and volatile.
109.34 has been pivotal.
Posted a bullish Flag formation.
A break of 109.34 is needed to confirm the outlook.
The bias is to break to the upside.
Our profit targets will be 117.51 and 119.51
Resistance: 108.50 / 109.34 / 112.95
Support: 106.80 / 105.96 / 104.00
Please be advised that the information presented on TradingView is provided to Vantage (‘Vantage Global Limited’, ‘we’) by a third-party provider (‘Everest Fortune Group’). Please be reminded that you are solely responsible for the trading decisions on your account. There is a very high degree of risk involved in trading. Any information and/or content is intended entirely for research, educational and informational purposes only and does not constitute investment or consultation advice or investment strategy. The information is not tailored to the investment needs of any specific person and therefore does not involve a consideration of any of the investment objectives, financial situation or needs of any viewer that may receive it. Kindly also note that past performance is not a reliable indicator of future results. Actual results may differ materially from those anticipated in forward-looking or past performance statements. We assume no liability as to the accuracy or completeness of any of the information and/or content provided herein and the Company cannot be held responsible for any omission, mistake nor for any loss or damage including without limitation to any loss of profit which may arise from reliance on any information supplied by Everest Fortune Group.
NOK Nokia Oyj Options Ahead of EarningsAnalyzing the options chain of NOK Nokia Oyj prior to the earnings report this week,
I would consider purchasing the 4usd strike price Calls with
an expiration date of 2023-9-15,
for a premium of approximately $0.15.
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
Looking forward to read your opinion about it.
Pfizer getting ready to make rapid movesPfizer is one of the world’s leading pharmaceutical company specializes in vaccines, hospitals, internal medicines and inflammation and immunology. Their manufacturing capacity is 4 billion tablets annually and supplied in neighboring countries of India.
Pfizer CMP is 3866. Negative aspects of the company are high valuation (P.E. = 28.3), MFs are decreasing stake. Positive aspects of the company are increasing annual net profits, improving cash from operations annual, no debt, FIIs are increasing stake and zero promoter pledge.
Entry can be taken after closing above 3901. Targets in the stock will be 3975 and 4006. Long term target in the stock will be 4069 and 4129. Stop loss in the stock should be maintained at closing below 3696.
Privi Speciality propending so special moves. Privi Specialty Chemicals Ltd. is the leading supplier and exporter of aroma and fragrance chemicals. The company expanded to manufacturing capacity of 50+ products to 40,000 tons per annum with a power of two manufacturing facilities situated in Mahad, Maharashtra and Jhagadia, Gujarat.
Privi Specialty Chemicals CMP is 1109.50. Negative aspects of the company are high valuation (P.E. = 194), declining annual net profits, declining cash from operations annual and MFs are decreasing stake. Positive aspects of the company are FIIs are increasing stake and zero promoter pledge.
Entry can be taken after closing above 1150. Targets in the stock will be 1198 and 1232. Long term target in the stock will be 1289 and 1357. Stop loss in the stock should be maintained at closing below 955.
QSI Growth Thesis ! ARK Biggest Shareholder Accumulating !Quantum-Si (QSI), currently trading at $1.55, presents an intriguing growth opportunity with the potential to at least double in value. Several factors contribute to this growth thesis:
Disruptive Technology: QSI's technology has the capability to revolutionize the discovery of new diagnostic tests and pharmaceuticals through digitization. By leveraging AI and digitizing the industry, QSI can significantly accelerate and reduce the cost of these discoveries. The implementation of AI has the potential to exponentially enhance the speed and efficiency of the process, positioning QSI at the forefront of innovation in the field.
Founder's Confidence: Jonathan Rothberg, the founder of QSI, has displayed unwavering confidence in the company's future. Notably, Rothberg has not sold a single share and, in fact, acquired tens of thousands of shares in the $3-4 range last year. This demonstrates his belief in the company's long-term potential, which is a rarity among new companies. In contrast to many other recent IPOs, where founders and CEOs have been selling shares, Rothberg's continued investment reflects his dedication and commitment to QSI's success.
Strong Financial Position: QSI boasts a robust financial position with over $330 million in cash and zero debt. This substantial cash reserve provides the company with a secure foundation and ample resources to fund operations for at least three years. This financial stability is uncommon for a company that went public through a SPAC, instilling confidence in QSI's ability to execute its plans without facing immediate financial constraints.
Strengthening Executive Team: QSI has been bolstering its executive team, attracting talented individuals from reputable companies such as ILMN (Illumina). This strategic move enhances QSI's expertise and further positions the company for successful execution of its plans. The addition of experienced professionals from a prominent industry player underscores QSI's commitment to assembling a capable team to drive growth and innovation.
ARK's Support: ARK, an influential investment firm, has been actively accumulating QSI shares, driving up demand and limiting the availability of public shares. With approximately 9.75% ownership in QSI and an average acquisition price of $9.91, ARK's confidence in the company's potential is evident. Their continued investments, as seen in their recent purchase worth $675K, signal a positive outlook for QSI and attract attention from other investors.
From a technical analysis perspective, Quantum-Si (QSI) appears to be forming a double bottom pattern, which can indicate a potential trend reversal and a bullish signal. The double bottom pattern is characterized by two distinct price lows, with a moderate upward price movement in between, forming a "W" shape on the chart.
In the case of QSI, the formation of a double bottom pattern suggests that selling pressure may be diminishing, and buyers could potentially step in to drive the stock's price higher. This pattern often signifies a shift in market sentiment from bearish to bullish.
Based on the double bottom pattern, some technical analysts may project a potential price target. In this case, the price target of $1.93 indicates the expected upside move if QSI breaks above the pattern's neckline or resistance level.
Considering these factors, Quantum-Si (QSI) presents an intriguing growth opportunity. The disruptive technology, founder's confidence, strong financial position, strengthened executive team, and support from influential investors contribute to a compelling investment thesis. While investments involve risks, QSI's current valuation of $1.55 potentially offers significant upside, with the potential for at least doubling in value based on the provided information.
Looking forward to read your opinion about it!
HOPL.N0000Entry Point: 38 - 46
Profit Target: 60+
Stop-Loss: 35
Disclaimer: The information and analysis provided in this publication are for educational purposes only and should not be construed as financial advice or recommendations to buy, sell, or hold any securities. The author and TradingView are not responsible for any investment decisions made based on the content presented herein. Always consult a financial professional before making any investment decisions.
AA Alcoa Corporation Options Ahead of EarningsAnalyzing the options chain of AA Alcoa Corporation prior to the earnings report this week,
I would consider purchasing the 40usd strike price Calls with
an expiration date of 2024-1-19,
for a premium of approximately 3.00usd.
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
Looking forward to read your opinion about it.
LIOC - Bullish divergence in daily chartEntry Point: 120 to 130
Profit Target: 180-200
Stop-Loss: 110
Disclaimer: The information and analysis provided in this publication are for educational purposes only and should not be construed as financial advice or recommendations to buy, sell, or hold any securities. The author and TradingView are not responsible for any investment decisions made based on the content presented herein. Always consult a financial professional before making any investment decisions.
Consol Energy to find buyers at previous resistance?Consol Energy - 30d expiry - We look to Buy at 63.75 (stop at 60.75)
We are trading at overbought extremes.
Previous resistance at 64 now becomes support.
The previous swing low is located at 63.32.
Bespoke support is located at 64.
We look to buy dips.
Expect trading to remain mixed and volatile.
Our profit targets will be 70.75 and 72.75
Resistance: 68.00 / 69.84 / 72.00
Support: 65.85 / 63.32 / 62.00
Please be advised that the information presented on TradingView is provided to Vantage (‘Vantage Global Limited’, ‘we’) by a third-party provider (‘Everest Fortune Group’). Please be reminded that you are solely responsible for the trading decisions on your account. There is a very high degree of risk involved in trading. Any information and/or content is intended entirely for research, educational and informational purposes only and does not constitute investment or consultation advice or investment strategy. The information is not tailored to the investment needs of any specific person and therefore does not involve a consideration of any of the investment objectives, financial situation or needs of any viewer that may receive it. Kindly also note that past performance is not a reliable indicator of future results. Actual results may differ materially from those anticipated in forward-looking or past performance statements. We assume no liability as to the accuracy or completeness of any of the information and/or content provided herein and the Company cannot be held responsible for any omission, mistake nor for any loss or damage including without limitation to any loss of profit which may arise from reliance on any information supplied by Everest Fortune Group.